Sector News

Valeant said to step up talks on potential $800M deal for Egypt’s Amoun

June 18, 2015
Life sciences
Last month, reports said Valeant was eyeing up one of Egypt’s largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.
 
The serial buyer is in advanced negotiations to buy Amoun Pharmaceutical, Bloomberg reports, though no final decision has been made–meaning any deal could still fall apart. A sale could value the company between $700 million and $800 million, the news service’s sources said in May.
 
If Valeant were to grab Amoun, it would mark its third buyout of the year. After losing out on a months-long hostile takeover try for Allergan last November, the avid dealmaker has already snapped up North Carolina’s Salix–beating out rival bidder Endo–and the assets from bankrupt Seattle biotech Dendreon in the first half of 2015.
 
But unlike those transactions–which helped the company bulk up in GI and oncology, respectively–an Amoun tie-up would strengthen Valeant in fast-growing emerging markets. Beefing up in developing nations was one perk of the proposed Allergan merger, and a goal Pearson has already worked toward with deals like 2012’s for Mexican branded-generics company Atlantis Pharma.
 
It’s all part of Valeant’s strategy to expand through M&A in high-growth spaces–both geographic and therapeutic. Before the Salix and Dendreon deals, Valeant’s moves–like the Allergan play, and its 2013 pickup of Bausch + Lomb–were centered on skincare and eye care, two other hot fields Pearson had tabbed for expansion.
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”